Factor XI (FXI) inhibitors are an emerging class of anticoagulant medications designed to prevent pathological blood clots (thrombosis) while maintaining a significantly lower risk of bleeding compared to traditional blood thinners.
A class of anticoagulant medications designed to prevent pathological blood clots (thrombosis) while maintaining a significantly lower risk of bleeding compared to traditional blood thinners.
Target: They act on the intrinsic coagulation pathway by inhibiting Factor XI or activated Factor XI (FXIa), which reduces thrombin generation and fibrin formation.
They uncouple thrombus expansion from normal hemostasis, meaning they block dangerous clotting without disrupting the body’s natural ability to stop everyday bleeding.
Main Drug Classes and Agents
Oral Small-Molecule Inhibitors (Active-Site Blockers): Asundexian and milvexian.
Monoclonal Antibodies: Abelacimab, osocimab, and xisomab.
Antisense Oligonucleotides (ASOs): Agents like IONIS-FXI-Rx and fesomersen that target hepatic synthesis to lower FXI production.
Atrial Fibrillation (AF): Investigated as a safer alternative to direct oral anticoagulants (DOACs) like apixaban or rivaroxaban, though trial results have varied stroke and Vascular Prevention:
Surgery and Dialysis: Tested for venous thromboembolism (VTE) prevention in major orthopedic surgery and for use in hemodialysis patients.
They act on the intrinsic coagulation pathway by inhibiting Factor XI or activated Factor XI (FXIa), which reduces thrombin generation and fibrin formation.
They uncouple thrombus expansion from normal hemostasis, meaning they block dangerous clotting without disrupting the body’s natural ability to stop everyday bleeding.
Oral Small-Molecule Inhibitors (Active-Site Blockers): Asundexian and milvexian.
Monoclonal Antibodies: Abelacimab, osocimab, and xisomab.
Antisense Oligonucleotides (ASOs): Agents like IONIS-FXI-Rx and fesomersen that target hepatic synthesis to lower FXI production.
Clinical Development and Indications
• Atrial Fibrillation (AF): Investigated as a safer alternative to direct oral anticoagulants (DOACs) like apixaban or rivaroxaban, though trial results have varied.
Stroke and Vascular Prevention: Evaluated in secondary stroke prevention and acute coronary syndromes.
Surgery and Dialysis: Tested for venous thromboembolism (VTE) prevention in major orthopedic surgery and for use in hemodialysis patients.